Bibliography
- CROOKE ST: Vitravene- another piece in the mosaic. Antisense Nucleic Acid Drug Dev. (1998) 8:7–8.
- UHLMANN E, PEYMAN A: Antisense oligonucleotides: a new therapeutic principle. Chem. Rev. (1990) 90:543–584.
- UHLMANN E: Recent advances in the medicinal chemistry of antisense oligonucleotides. Curr. Opin. Drug Discov. Dev. (2000) 3:203–213.
- WANG H, CAI Q, ZENG X, YU D, AGRAWAL S, ZHANG R: Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RI a subunit of protein kinase A after oral administration. Proc. Natl. Acad. Sci. USA (1999) 96:13989–13994.
- UHLMANN E, PEYMAN A, RYTE A, SCHMIDT A, BUDDECKE E: Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression. Methods Enzymol. (1999) 313:268–284.
- WENGEL J: Synthesis of 3'-C- and 4'-C-branched ofigodeoxynucleotides and the development of locked nucleic acid (LNA). Acc. Chem. Res. (1999) 32:301–310.
- WAHLESTEDT C, SALMI P, GOOD L et al.: Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. USA. (2000) 97:5633–5638.
- STETSENKO DA, GAIT MJ: Efficient conjugation of peptides to oligonucleotides by 'native ligation'. J. Org. Chem. (2000) 65:4900–4908.
- COTTER FE, WATERS J, CUNNINGHAM D: Human Bc1-2 antisense therapy for lymphomas. Biochim. Biophys. Acta (1999)1489: 97–106.
- KRIEG AM: DNA-based immune enhancers. Curr. Opin. Drug Discov. Dev. (2000) 3:214–221.
- AGRAWAL S: Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim. Biophys. Acta (1999) 1489:53–68.
- YU D, ZHAO Q, KANDIMALLA ER, AGRAWAL S: Accessible 5'-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for irnmunostimulatory activity. Bioorgan. Med. Chem. Lett. (2000) 10:2585–2588.
- KLUSSMANN S, NOLTE A, BALD R, ERDMANN V, FUERSTE JP: Mirror-image RNA that binds D-adenosine. Nat. Biotechnol. (1996) 14:1112–1115.
- HOLMLUND JT, MONIA BP, KWOH TJ, DORR FA: Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development. Curr. Opin. Mol. Ther. (1999) 1:372–385.